PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 17, 2026CancersOpen Access

BCAR3 Hypomethylation as a Potential Diagnostic Marker for Thyroid Cancer and Its Mechanism via Promoting EMT and AKT/mTOR Pathway

View Full Paper
Ask AI
Bookmark
Share

Authors

WYWenkang YuYMYizhu MaoYYYifei Yin

Discussion

Loading...

Member takes

Overview

Investigates BCAR3's role in thyroid cancer, finding hypomethylation linked to increased tumor activities, suggesting diagnostic potential.

Key Points

  • The study aims to explore BCAR3 methylation status and its functional impacts in thyroid cancer.
  • Analyzed BCAR3 methylation using MALDI-TOF mass spectrometry in 422 thyroid cancer and 371 benign samples.
  • Assessed BCAR3 expression via immunohistochemistry, qPCR, and Western blot.
  • Conducted functional assays focusing on proliferation, migration, and invasion after BCAR3 knockdown.
  • Performed rescue experiments with a PI3K activator to determine mechanistic pathways.
  • BCAR3 was hypomethylated in thyroid cancer compared to benign tissues (p < 0.001).
  • The strongest association with thyroid cancer risk was observed in CpG_6 (OR = 1.73, p < 0.001).
  • Larger tumor size and advanced disease stage correlated with increased BCAR3 hypomethylation.
  • BCAR3 expression was upregulated in thyroid cancer tissues and cell lines (p < 0.05).
  • Knockdown of BCAR3 reduced AKT/mTOR phosphorylation and changed EMT marker expression, suppressing cell proliferation, migration, and invasion (p < 0.05).

Cite This Study

Yu et al. (2026) studied this question.

synapsesocial.com/papers/696b25cfd2a12237a93492c9https://doi.org/10.3390/cancers18020267
View Full Paper
Ask AI
Bookmark
Share